The bioplatform provided a LOD of 2.9 fmol for the synthetic target DNA and allowed a clear discrimination towards the single base mutated TP53 sequence (missense mutation G → A in codon 175 leading to cancer-triggering deactivation of the tumor suppressor protein p53). Here, TP53 is linked to cancer.